{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:58:51Z","timestamp":1793311131987,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ijrobp.2021.08.008","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T23:13:00Z","timestamp":1628896380000},"page":"146-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Long-Term Outcomes of NRG Oncology\/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer"],"prefix":"10.1016","volume":"112","author":[{"given":"Lisa A.","family":"Kachnic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Myerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Goodyear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre A.","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar E.","family":"Streeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Augspurger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey E.","family":"Schefter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan W.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Henke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.08.008_bib0001","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: a preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0002","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0003","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0004","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0005","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0006","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin\/5FU in squamous cell carcinoma of the anus (ACT II)","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0007","first-page":"205","article-title":"Dose escalation in chemoradiation for anal cancer: Preliminary results of RTOG 92-08","volume":"2","author":"John","year":"1996","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0008","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0360-3016(96)00146-0","article-title":"Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): An Eastern Cooperative Oncology Group study","volume":"35","author":"Martenson","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0009","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 Phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0010","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/sj.bjc.6690567","article-title":"Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy","volume":"80","author":"Allal","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0011","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0167-8140(99)00096-1","article-title":"Curative intent radiation therapy in anal carcinoma: Quality of life and sphincter function","volume":"52","author":"Vordermark","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0012","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1001\/jama.294.20.2587","article-title":"Risk of pelvic fractures in older women following pelvic radiation","volume":"294","author":"Baxter","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0013","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: A pooled data analysis of radiation therapy oncology group trials 87-04 and 98-11","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0014","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijrobp.2005.02.030","article-title":"Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: Toxicity and clinical outcome","volume":"63","author":"Milano","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0015","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2007.12.0170","article-title":"Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: A multicenter experience","volume":"25","author":"Salama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0016","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","article-title":"Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy","volume":"82","author":"Kachnic","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.prro.2012.02.005","article-title":"Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic institution","volume":"3","author":"Call","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0018","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/COC.0000000000000009","article-title":"Intensity-modulated radiation therapy for anal cancer: Results from a multi-institutional retrospective cohort study","volume":"39","author":"Call","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0019","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.adro.2017.01.009","article-title":"Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529","volume":"2","author":"Mitra","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0021","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ijrobp.2007.09.018","article-title":"Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer","volume":"70","author":"Cannon","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0022","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: A radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0023","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0024","series-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"1980"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J Royal Stat Soc Series B"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0026","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the sub-distribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0027","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.ijrobp.2010.04.011","article-title":"Marginal misses after postoperative intensity-modulated radiotherapy for head and neck cancer","volume":"80","author":"Chen","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl","key":"10.1016\/j.ijrobp.2021.08.008_bib0028","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1200\/jco.2008.26.15_suppl.4608","volume":"26","author":"Vuong","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0029","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ijrobp.2006.01.009","article-title":"FDG-PET\/CT in the evaluation of anal carcinoma","volume":"65","author":"Cotter","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.radonc.2018.10.021","article-title":"Intensity-modulated radiation therapy of anal squamous cell carcinoma: Relationship between delineation quality and regional recurrence","volume":"131","author":"Rouard","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0031","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12032-018-1118-3","article-title":"Genital marginal failures after intensitymodulated radiation therapy (IMRT) in squamous cell anal cancer: No higher risk with IMRT when compared to 3DCRT","volume":"35","author":"Dell'Acqual","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0032","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2009.09.029","article-title":"Squamous cell carcinoma of the anal canal: Patterns and predictors of failure and implications for intensity-modulated radiation treatment planning","volume":"78","author":"Wright","year":"2010","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0033","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijrobp.2019.10.016","article-title":"Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma","volume":"106","author":"Shakir","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0034","unstructured":"ECOG-ACRIN 2182: A randomized phase II study of de-Intensified chemoradiation for early-stage anal squamous cell carcinoma (DECREASE). Clinicaltrials.gov NCT04166318. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04166318. Accessed Nov 21, 2021."},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.radonc.2020.05.018","article-title":"Patterns of inguinal node metastases in anal canal cancer and recommendations for elective clinical target volume (CTV) delineation","volume":"149","author":"Garda","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0036","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1200\/JCO.2008.19.6857","article-title":"US intergroup anal carcinoma trial: Tumor diameter predicts for colostomy","volume":"27","author":"Ajani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0037","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cncr.27825","article-title":"Prognostic factors in anal cancer: Generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I)","volume":"119","author":"Glynne-Jones","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0038","first-page":"356","article-title":"Predictors of radiation therapy-related gastrointestinal toxicity from anal cancer dose-painted intensity modulated radiation therapy: Secondary analysis of NRG Oncology RTOG 0529","volume":"7","author":"Olsen","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0039","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncr.24906","article-title":"Long-term quality of life after radiotherapy for the treatment of anal cancer","volume":"116","author":"Das","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.prro.2014.09.003","article-title":"Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer","volume":"5","author":"Mirabeau-Beale","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0041","unstructured":"PLATO ACT 5: A trial looking at higher doses of chemoradiotherapy for people with locally advanced anal cancer. Cancer Research UK {CRUK) 14592. Available at:https:\/\/www.cancerresearchuk.org\/about-cancer\/find-a-clinical-trial\/a-trial-looking-at-higher-doses-of-chemoradiotherapy-for-people-with-locally-advanced-anal-cancer. Accessed November 21, 2021."},{"key":"10.1016\/j.ijrobp.2021.08.008_bib0042","unstructured":"ECOG-ACRIN 2165: Nivolumab after combined modality therapy in treating patients with high risk stage II-IIIB anal cancer. Clinicaltrials.gov NCT03233711. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03233711. Accessed November 12, 2021."}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162102647X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162102647X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:55:28Z","timestamp":1759744528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162102647X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S036030162102647X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.08.008","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Outcomes of NRG Oncology\/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}